标题
Chronic lymphocytic leukaemia: from genetics to treatment
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-07-05
DOI
10.1038/s41571-019-0239-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
- (2019) Anas Younes et al. Lancet Haematology
- Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia
- (2019) Federico Gaiti et al. NATURE
- Biology and treatment of Richter syndrome
- (2018) Davide Rossi et al. BLOOD
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
- (2018) Jeffrey Jones et al. BRITISH JOURNAL OF HAEMATOLOGY
- In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics
- (2018) Gian Matteo Rigolin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
- (2018) Andreas Agathangelidis et al. HAEMATOLOGICA
- Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia
- (2018) Idanna Innocenti et al. HEMATOLOGICAL ONCOLOGY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia
- (2018) Renée Beekman et al. NATURE MEDICINE
- Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
- (2018) Jan A. Burger et al. Nature Reviews Clinical Oncology
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
- (2018) Andreas Agathangelidis et al. HAEMATOLOGICA
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic landscape and deregulated pathways in B-cell lymphoid malignancies
- (2017) R. Rosenquist et al. JOURNAL OF INTERNAL MEDICINE
- Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity
- (2017) S Marsilio et al. LEUKEMIA
- Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
- (2017) F Nadeu et al. LEUKEMIA
- NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways
- (2017) D Benedetti et al. LEUKEMIA
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components
- (2017) F Pozzo et al. LEUKEMIA
- Common nonmutationalNOTCH1activation in chronic lymphocytic leukemia
- (2017) Giulia Fabbri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia
- (2017) Philip J. Law et al. Nature Communications
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- (2017) Dan A. Landau et al. Nature Communications
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
- (2017) Jeffrey A Jones et al. Lancet Haematology
- Whole exome sequencing in families with CLL detects a variant in Integrin 2 associated with disease susceptibility
- (2016) L. R. Goldin et al. BLOOD
- Clinical impact of MYD88 mutations in chronic lymphocytic leukemia
- (2016) A. Martinez-Trillos et al. BLOOD
- Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
- (2016) F. Nadeu et al. BLOOD
- Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
- (2016) C. D. Herling et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
- (2016) Lili Wang et al. CANCER CELL
- A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
- (2016) N. A. Amin et al. CLINICAL CANCER RESEARCH
- Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
- (2016) Lijian Yu et al. CLINICAL CANCER RESEARCH
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- Antigen receptor stereotypy in chronic lymphocytic leukemia
- (2016) K Stamatopoulos et al. LEUKEMIA
- Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome
- (2016) S Barrio et al. LEUKEMIA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Richter syndrome: pathogenesis and management
- (2016) Davide Rossi et al. SEMINARS IN ONCOLOGY
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- A nationwide population-based cross-sectional comparison of hematological malignancies incidences between Taiwan and the United States of America
- (2015) Shang-Ju Wu et al. ANNALS OF HEMATOLOGY
- Prognostic relevance of MYD88 mutations in CLL: the jury is still out
- (2015) P. Baliakas et al. BLOOD
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification
- (2015) P. Strati et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
- (2015) V. Ljungstrom et al. BLOOD
- Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
- (2015) Larry Mansouri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation
- (2015) F Pozzo et al. LEUKEMIA
- Non-coding recurrent mutations in chronic lymphocytic leukaemia
- (2015) Xose S. Puente et al. NATURE
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution
- (2015) S. Kasar et al. Nature Communications
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
- (2014) A. Martinez-Trillos et al. BLOOD
- Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness
- (2014) M. Messina et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia
- (2014) Dan A. Landau et al. CANCER CELL
- Immunogenetic Studies of Chronic Lymphocytic Leukemia: Revelations and Speculations about Ontogeny and Clinical Evolution
- (2014) A. Vardi et al. CANCER RESEARCH
- Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression
- (2014) J Ojha et al. LEUKEMIA
- Recurrent mutations refine prognosis in chronic lymphocytic leukemia
- (2014) P Baliakas et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients
- (2014) F. Damm et al. Cancer Discovery
- Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
- (2013) E. Chigrinova et al. BLOOD
- TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
- (2013) P. Dreger et al. BLOOD
- Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
- (2013) P. Abrisqueta et al. BLOOD
- Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL
- (2013) A. Vardi et al. BLOOD
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
- (2013) Giulia Fabbri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients
- (2013) S Weissmann et al. LEUKEMIA
- Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia
- (2013) F Arruga et al. LEUKEMIA
- SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
- (2013) S Jeromin et al. LEUKEMIA
- The role ofATMmutations and 11q deletions in disease progression in chronic lymphocytic leukemia
- (2013) Tatjana Stankovic et al. LEUKEMIA & LYMPHOMA
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia
- (2013) Andrew J Ramsay et al. NATURE GENETICS
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
- (2012) A. Agathangelidis et al. BLOOD
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial
- (2012) D. G. Oscier et al. BLOOD
- Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia
- (2012) Fabio P. S. Santos et al. CANCER JOURNAL
- Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Kate Cwynarski et al. JOURNAL OF CLINICAL ONCOLOGY
- Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial
- (2012) Anna Skowronska et al. JOURNAL OF CLINICAL ONCOLOGY
- Cellular origin and pathophysiology of chronic lymphocytic leukemia
- (2012) Marc Seifert et al. JOURNAL OF EXPERIMENTAL MEDICINE
- NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia
- (2012) L Mansouri et al. LEUKEMIA
- NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
- (2012) N Villamor et al. LEUKEMIA
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
- (2012) Li Ding et al. NATURE
- Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
- (2012) Marta Kulis et al. NATURE GENETICS
- The Notch signalling system: recent insights into the complexity of a conserved pathway
- (2012) K. G. Guruharsha et al. NATURE REVIEWS GENETICS
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- NOTCH1 mutations in CLL associated with trisomy 12
- (2011) V. Balatti et al. BLOOD
- Alteration of BIRC3 and multiple other NF- B pathway genes in splenic marginal zone lymphoma
- (2011) D. Rossi et al. BLOOD
- Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
- (2011) D. Rossi et al. BLOOD
- Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
- (2011) D. Rossi et al. BLOOD
- The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
- (2011) D. Rossi et al. BLOOD
- Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia
- (2011) Yoshikane Kikushige et al. CANCER CELL
- NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL
- (2011) I. Del Giudice et al. HAEMATOLOGICA
- Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia
- (2011) Martin Trbusek et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
- (2011) David Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia
- (2011) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of the chronic lymphocytic leukemia coding genome: role ofNOTCH1mutational activation
- (2011) Giulia Fabbri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults
- (2011) J Almeida et al. LEUKEMIA
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
- (2011) Víctor Quesada et al. NATURE GENETICS
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- 13q14 deletions in CLL involve cooperating tumor suppressors
- (2010) A. Palamarchuk et al. BLOOD
- The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect
- (2010) S.-J. Wu et al. BLOOD
- The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia
- (2010) Ulf Klein et al. CANCER CELL
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management
- (2010) T D Shanafelt et al. LEUKEMIA
- Therapeutic antibody targeting of individual Notch receptors
- (2010) Yan Wu et al. NATURE
- Prognostic factors in chronic lymphocytic leukemia—what do we need to know?
- (2010) Paula Cramer et al. Nature Reviews Clinical Oncology
- Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
- (2009) P. Abrisqueta et al. BLOOD
- Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach
- (2009) W. G. Nieto et al. BLOOD
- Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
- (2009) Francesc Bosch et al. JOURNAL OF CLINICAL ONCOLOGY
- B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia
- (2009) Ola Landgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring
- (2008) A. Dagklis et al. BLOOD
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- (2008) T. Zenz et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression
- (2008) Tait D. Shanafelt et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
- (2008) Andy C. Rawstron et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started